Sugammadex and ideal body weight in bariatric surgery.

PubWeight™: 0.85‹?›

🔗 View Article (PMC 3690214)

Published in Anesthesiol Res Pract on June 06, 2013

Authors

Maria Sanfilippo1, Francesco Alessandri, Ahmed Abdelgawwad Wefki Abdelgawwad Shousha, Antonio Sabba, Alessandra Cutolo

Author Affiliations

1: Department of Anesthesiology and Intensive Care, Sapienza University, Viale del Policlinico 155, 00161 Rome, Italy.

Associated clinical trials:

Pharmacokinetics and Pharmacodynamics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade | NCT04131218

Articles citing this

Sugammadex and ideal body weight in bariatric surgery: the debate continues. Anesthesiol Res Pract (2014) 0.75

Articles cited by this

Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand (2007) 2.77

Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg (2007) 2.17

Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology (2006) 1.96

A randomized, dose-finding, phase II study of the selective relaxant binding drug, Sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg (2007) 1.87

A randomized simultaneous comparison of acceleromyography with a peripheral nerve stimulator for assessing reversal of rocuronium-induced neuromuscular blockade with sugammadex. Eur J Anaesthesiol (2010) 1.54

Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem (2002) 1.46

A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl (2002) 1.46

Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology (2003) 1.26

Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth (2010) 1.21

Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology (2007) 1.19

Clinical pharmacokinetics of drugs in obesity. An update. Clin Pharmacokinet (1993) 1.15

Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther (1981) 1.12

A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg (2007) 1.05

Pharmacokinetics of drugs in obesity. Clin Pharmacokinet (1982) 1.04

Sugammadex in clinical practice. Anaesthesia (2009) 1.03

The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients. Anesth Analg (2004) 1.00

Sugammadex: a review of its use in anaesthetic practice. Drugs (2009) 0.99

Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med (1983) 0.98

Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. Anesthesiology (2011) 0.97

Bariatric surgery. Surgery for weight control in patients with morbid obesity. Med Clin North Am (2000) 0.95

Increased glomerular filtration rate and adrenocortical function in obese women. Int J Obes (1980) 0.87

Low-dose rocuronium and tracheal intubation. Middle East J Anaesthesiol (2003) 0.78

Onset of the nondepolarizing neuromuscular block in humans: quantitative aspects. Anesth Analg (1993) 0.78

Articles by these authors

Emergence in elderly patient undergoing general anesthesia with xenon. Case Rep Anesthesiol (2013) 0.79